

Joshua T Kantrowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7720745/publications.pdf>

Version: 2024-02-01

86
papers

3,656
citations

147786

31
h-index

138468

58
g-index

92
all docs

92
docs citations

92
times ranked

4525
citing authors

#	ARTICLE	IF	CITATIONS
1	N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. <i>Brain Research Bulletin</i> , 2010, 83, 108-121.	3.0	340
2	Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. <i>Molecular Psychiatry</i> , 2018, 23, 1764-1772.	7.9	253
3	High dose D-serine in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2010, 121, 125-130.	2.0	207
4	Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. <i>Molecular Psychiatry</i> , 2014, 19, 20-29.	7.9	181
5	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. <i>Schizophrenia Research</i> , 2014, 152, 325-332.	2.0	144
6	Glutamatergic transmission in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2012, 25, 96-102.	6.3	141
7	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. <i>Lancet Psychiatry</i> , 2015, 2, 403-412.	7.4	128
8	Auditory Emotion Recognition Impairments in Schizophrenia: Relationship to Acoustic Features and Cognition. <i>American Journal of Psychiatry</i> , 2012, 169, 424-432.	7.2	99
9	Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 4, 189-200.	1.4	98
10	Neural mechanisms of mismatch negativity dysfunction in schizophrenia. <i>Molecular Psychiatry</i> , 2017, 22, 1585-1593.	7.9	92
11	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. <i>Schizophrenia Research</i> , 2018, 191, 70-79.	2.0	88
12	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. <i>JAMA Psychiatry</i> , 2018, 75, 11.	11.0	88
13	Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. <i>Brain</i> , 2016, 139, 3281-3295.	7.6	84
14	Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. <i>Journal of Neuroscience</i> , 2015, 35, 14909-14921.	3.6	80
15	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 1317-1323.	5.4	80
16	Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 51-60.	2.0	79
17	Seeing the World Dimly: The Impact of Early Visual Deficits on Visual Experience in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 1085-1094.	4.3	77
18	Single-Dose Ketamine Followed by Daily &span style="font-variant:small-caps;"&span>-Cycloserine in Treatment-Resistant Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 737-738.	2.2	63

#	ARTICLE	IF	CITATIONS
19	GABAB Receptors, Schizophrenia and Sleep Dysfunction. <i>CNS Drugs</i> , 2009, 23, 681-691.	5.9	62
20	Reduction in Tonal Discriminations Predicts Receptive Emotion Processing Deficits in Schizophrenia and Schizoaffective Disorder. <i>Schizophrenia Bulletin</i> , 2013, 39, 86-93.	4.3	59
21	A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. <i>Schizophrenia Research</i> , 2015, 164, 136-142.	2.0	59
22	Sleep disturbances in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , 2017, 249, 240-243.	3.3	58
23	Olanzapine: review of safety 2008. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 761-769.	2.4	56
24	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 419.	4.8	45
25	The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. <i>Psychological Medicine</i> , 2014, 44, 25-36.	4.5	43
26	Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. <i>Brain Stimulation</i> , 2019, 12, 981-991.	1.6	39
27	Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1079-1091.	2.8	38
28	New discoveries for an old drug: a review of recent olanzapine research. <i>Postgraduate Medicine</i> , 2020, 132, 80-90.	2.0	38
29	Managing Negative Symptoms of Schizophrenia: How Far Have We Come?. <i>CNS Drugs</i> , 2017, 31, 373-388.	5.9	37
30	Neurophysiological Effects of Bitopertin in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 447-451.	1.4	36
31	Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians. <i>Psychiatric Quarterly</i> , 2009, 80, 213-218.	2.1	34
32	Three cases of risperidone-induced enuresis. <i>Schizophrenia Research</i> , 2006, 84, 174-175.	2.0	32
33	A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 10-17.	2.0	32
34	N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. <i>Schizophrenia Research</i> , 2019, 207, 70-79.	2.0	32
35	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglometad and TS-134 on ketamine-induced psychotic symptoms and pharmacBOLD in healthy volunteers. <i>Neuropsychopharmacology</i> , 2020, 45, 1842-1850.	5.4	32
36	Synaptic Depolarizing GABA Response in Adults Is Excitatory and Proconvulsive When GABAB Receptors Are Blocked. <i>Journal of Neurophysiology</i> , 2005, 93, 2656-2667.	1.8	30

#	ARTICLE	IF	CITATIONS
37	Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. Expert Review of Neurotherapeutics, 2009, 9, 1045-1058.	2.8	30
38	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology, 2020, 45, 1339-1345.	5.4	30
39	Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. Schizophrenia Research, 2018, 191, 140-147.	2.0	29
40	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. Translational Psychiatry, 2019, 9, 221.	4.8	28
41	Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. CNS Drugs, 2020, 34, 947-959.	5.9	28
42	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. NeuroImage: Clinical, 2019, 22, 101739.	2.7	27
43	Amusia and protolanguage impairments in schizophrenia. Psychological Medicine, 2014, 44, 2739-2748.	4.5	24
44	Schizoaffective Disorder. CNS Drugs, 2011, 25, 317-331.	5.9	23
45	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processingâ€œFocused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychiatry, 2016, 77, 799-806.	2.2	22
46	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Research, 2019, 275, 78-85.	3.3	21
47	Risk of psychosis exacerbation by tricyclic antidepressants in unipolar Major Depressive Disorder with psychotic features. Journal of Affective Disorders, 2008, 106, 279-284.	4.1	16
48	The importance of a good night's sleep: An open-label trial of the sodium salt of Î³-hydroxybutyric acid in insomnia associated with schizophrenia. Schizophrenia Research, 2010, 120, 225-226.	2.0	16
49	Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartateâ€œ Type Glutamate Receptor Function. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 581-590.	1.5	16
50	D-Serine: A Cross Species Review of Safety. Frontiers in Psychiatry, 2021, 12, 726365.	2.6	16
51	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. Comprehensive Psychiatry, 2014, 55, 1862-1874.	3.1	15
52	<scpd>-Cycloserine, an NMDA Glutamate Receptor Glycine Site Partial Agonist, Induces Acute Increases in Brain Glutamate Plus Glutamine and GABA Comparable to Ketamine. American Journal of Psychiatry, 2016, 173, 1241-1242.	7.2	15
53	Neural and functional correlates of impaired reading ability in schizophrenia. Scientific Reports, 2019, 9, 16022.	3.3	15
54	The Potential Role of Lumateperoneâ€œSomething Borrowed? Something New?. JAMA Psychiatry, 2020, 77, 343.	11.0	15

#	ARTICLE	IF	CITATIONS
55	Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 525-526.	1.4	14
56	It's all in the cards: effect of stimulus manipulation on Wisconsin Card Sorting Test performance in schizophrenia. <i>Psychiatry Research</i> , 2009, 168, 198-204.	3.3	14
57	Elevated Plasma Dopamine Metabolites in Cannabis Psychosis. <i>American Journal of Psychiatry</i> , 2007, 164, 1615-1616.	7.2	12
58	A review of tolerability and abuse liability of Î³-hydroxybutyric acid for insomnia in patients with schizophrenia. <i>Clinical Therapeutics</i> , 2009, 31, 1360-1373.	2.5	12
59	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2008, 2, 261-71.	4.7	12
60	The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. <i>Schizophrenia Research</i> , 2022, 242, 56-61.	2.0	12
61	Lurasidone for schizophrenia: whatâ€™s different?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 265-273.	2.8	11
62	Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 199-210.	4.3	11
63	Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 629144.	2.6	10
64	Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. <i>Neuropsychopharmacology</i> , 2022, 47, 711-718.	5.4	10
65	Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 653026.	2.6	9
66	Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. <i>CNS Drugs</i> , 2021, 35, 1153-1161.	5.9	9
67	The 3rd Schizophrenia International Research Society Conference, 14â€“18 April 2012, Florence, Italy: Summaries of oral sessions. <i>Schizophrenia Research</i> , 2012, 141, e1-e24.	2.0	8
68	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 0, .	4.7	6
69	Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia. , 2009, , 39-89.		6
70	How do we address treating the negative symptoms of schizophrenia pharmacologically?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1811-1813.	1.8	6
71	Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2022, 48, 1284-1294.	4.3	5
72	Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia. <i>International Journal of Psychophysiology</i> , 2016, 108, 37.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Additional perspective on cariprazine and negative symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1469-1470.	1.8	3
74	Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. <i>Schizophrenia Research</i> , 2020, 218, 321-323.	2.0	2
75	Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , 2020, 5, .	0.5	1
76	Improving the reproducibility of proton magnetic resonance spectroscopy brain thermometry: Theoretical and empirical approaches. <i>NMR in Biomedicine</i> , 2022, 35, e4749.	2.8	1
77	Resolution of Transient Ischemic Attacks and Aortic Arch Thrombi on Anticoagulant Therapy. <i>European Neurology</i> , 2000, 43, 184-185.	1.4	0
78	Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD). <i>The Cochrane Library</i> , 0, , .	2.8	0
79	Poster #196 HIGH DOSE D-SERINE IN THE TREATMENT OF SCHIZOPHRENIA. <i>Schizophrenia Research</i> , 2012, 136, S351.	2.0	0
80	428. Neurophysiological Mechanisms of Cortical Learning Plasticity Impairments in Schizophrenia and Modulation by the N-Methyl-D-Aspartate Type Glutamate Receptor Agonist D-Serine. <i>Biological Psychiatry</i> , 2017, 81, S174-S175.	1.3	0
81	F181. A Randomized, Single-Blind, Parallel-Group Study to Evaluate the Effects of TS-134 on Ketamine-Induced Bold Signals in Resting fMRI in Healthy Adult Subjects. <i>Biological Psychiatry</i> , 2019, 85, S283-S284.	1.3	0
82	117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment. <i>Biological Psychiatry</i> , 2019, 85, S49.	1.3	0
83	CVN058, a 5-HT3 Receptor Antagonist, Shows Acute, Dose Dependent Improvement of Mismatch Negativity in a Double-Blind, Placebo-Controlled, Single Dose Cross-Over Study in Schizophrenia and Schizoaffective Disorder. <i>Biological Psychiatry</i> , 2021, 89, S27.	1.3	0
84	D-Serine Safety: A Cross Species Review. <i>Biological Psychiatry</i> , 2021, 89, S198.	1.3	0
85	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1008-e1008.	2.2	0
86	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1353-e1353.	2.2	0